Research Analysts Issue Forecasts for Cingulate Q1 Earnings

Key Points

• Ascendiant Capital Markets projects Q1 2027 EPS of ($0.37) for Cingulate and maintains a Buy rating with a $55 price target, while the Street consensus averages a Hold rating and a $34.50 price target.
• Cingulate reported ($0.84) EPS in its most recent quarter, missing estimates by $0.28; the stock opened at $5.50 with a market cap of about $64 million and a 12‑month range of $3.20–$11.89.
• Company insiders (including the CEO and a director) bought 33,074 shares over the last three months—insider ownership is 4.33%—and institutional investors own 41.31% of the stock.

Cingulate Inc. (NASDAQ:CING - Free Report) - Ascendiant Capital Markets issued their Q1 2027 earnings per share (EPS) estimates for Cingulate in a research report issued on Tuesday, April 7th. Ascendiant Capital Markets analyst E. Woo anticipates that the company will post earnings of ($0.37) per share for the quarter. Ascendiant Capital Markets has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Cingulate's current full-year earnings is ($11.69) per share. Ascendiant Capital Markets also issued estimates for Cingulate's Q2 2027 earnings at ($0.37) EPS, Q3 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.39) EPS.

Several other equities research analysts have also issued reports on CING. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Cingulate in a research note on Wednesday, January 21st. Roth Mkm lowered their target price on Cingulate from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, March 23rd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $34.50.

Cingulate Trading Down 4.5%

Shares of CING stock opened at $5.50 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average price of $6.77 and a two-hundred day moving average price of $5.11. Cingulate has a 12-month low of $3.20 and a 12-month high of $11.89. The firm has a market cap of $63.97 million, a P/E ratio of -1.27 and a beta of -0.76.

Cingulate (NASDAQ:CING - Get Free Report) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.28).

Insider Transactions at Cingulate

In related news, CEO Shane J. Schaffer bought 6,809 shares of the stock in a transaction dated Friday, February 6th. The stock was bought at an average price of $5.04 per share, with a total value of $34,317.36. Following the purchase, the chief executive officer owned 10,175 shares in the company, valued at approximately $51,282. The trade was a 202.29% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Peter J. Werth bought 19,455 shares of the stock in a transaction dated Friday, February 6th. The stock was bought at an average cost of $5.04 per share, with a total value of $98,053.20. Following the purchase, the director owned 117,449 shares in the company, valued at $591,942.96. The trade was a 19.85% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 33,074 shares of company stock valued at $166,693. 4.33% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cingulate

A number of hedge funds and other institutional investors have recently modified their holdings of CING. Bank of America Corp DE increased its holdings in Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company's stock valued at $31,000 after purchasing an additional 5,543 shares during the period. Soltis Investment Advisors LLC purchased a new position in Cingulate during the 4th quarter valued at about $43,000. XTX Topco Ltd purchased a new position in Cingulate during the 2nd quarter valued at about $45,000. Quantum Private Wealth LLC increased its holdings in Cingulate by 140.0% during the 3rd quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company's stock valued at $94,000 after purchasing an additional 14,000 shares during the period. Finally, Quadrature Capital Ltd purchased a new position in Cingulate during the 4th quarter valued at about $66,000. Institutional investors own 41.31% of the company's stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.